Please login to the form below

Not currently logged in
Email:
Password:

Takeda remains robust

Japanese firm posts strong net income but falling revenues for Q1 as the strength of the yen takes its toll

Takeda has posted a strong net income of 112.6bn yen ($1.2bn) for the first quarter, up from 2.5bn yen ($26m) in the same reporting period last year and some 30.1bn yen above analysts' expectations.

In the three months ended June 30, the Japanese company saw sales of a number of its leading products fall due to the strength of the yen. Revenue from type 2 diabetes treatment Actos fell 6.6 per cent to 96.4bn yen ($1bn), while sales of Takepron dropped 2.6 per cent to 70.5bn yen ($736m) and Blopress revenues fell 5.5 per cent to 56.6bn yen ($591m). Net sales for the period fell 4.5 per cent (17.9bn yen) to 379bn yen ($4bn).

Daiichi suffers loss
Japan's third-largest manufacturer, Daiichi Sankyo has reported a loss of 6.4bn yen ($67m) in the three months to June 30 compared with a net income of 25.1bn yen ($263m) for the first quarter of 2008.

The company's quarterly sales were up 11.5 per cent to 227.1bn yen ($2.4bn), of which 29.6bn yen ($310m) came from Ranbaxy of which Daiichi Sankyo is a majority shareholder.

Ordinary income has been upwardly revised to 37bn yen ($389m) from 20bn yen ($210m) and net income has been upwardly revised to 11bn yen ($115m), up 3bn yen ($31.5m). The earnings forecast for the full fiscal year remain unchanged.

3rd August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics